
-
Gold tops $3,000 for first time on Trump tariff war, stocks rebound
-
Putin tells Ukraine troops in Russian region to 'surrender'
-
Crew launch to ISS paves way for 'stranded' astronauts' return
-
Sean 'Diddy' Combs pleads not guilty to new indictment
-
Marc Marquez on top in Argentina MotoGP practice
-
Putin, Maduro vow to boost ties in wake of Trump sanctions
-
Sherratt says Wales need 'fresh' coach as Six Nations stint ends against England
-
New Canada PM Carney says Canada will never be part of US
-
Putin calls on Ukraine troops in Russian region to 'surrender'
-
Itoje urges England to 'take game to Wales' in Six Nations finale
-
Dozens evacuated in Italy's flood-hit Tuscany
-
Ebola-infected monkeys cured with a pill, raising hopes for humans: study
-
Mexicans seek answers after bones, shoes found at cartel camp
-
Triumphant Pedersen finds cold comfort on shivering 'Race to the Sun'
-
Greenland party leaders call Trump's behaviour 'unacceptable'
-
United G7 warns Russia to back Ukraine truce
-
Gold tops $3,000 for first time on Trump tariff threats; stocks rebound
-
Inothewayurthinkin denies Mullins, Galopin Des Champs Gold Cup hat-trick
-
Inothewayurthinkin beats Galopin Des Champs to win Cheltenham Gold Cup
-
Sebastian Coe criticises IOC election process
-
Israel PM, security agency fight it out in public
-
Courtois returns from Belgium exile for Nations League duty
-
Dupont absence 'changes nothing' for Alldritt before France's Six Nations decider
-
Russia 'committed crimes against humanity' in Ukraine: UN probe
-
Trump hails 'productive' truce talks with Russia, urges Putin to spare Ukrainians
-
Hundreds of Olympians call on IOC candidates to make climate top priority
-
Florence cathedral closed as Italy's Tuscany on flood alert
-
Mark Carney: Canada's new PM charted unusual path to power
-
Arteta 'proud' of Lewis-Skelly's England call-up
-
Mark Carney sworn in as Canada PM
-
US govt shutdown in balance after top Democrat avoids fight
-
Pope marks month in hospital as footballers send messages
-
Crew launch to ISS paves way for stranded astronauts' homecoming
-
Hamas says ready to free Israeli-US hostage, four bodies
-
Wainwright says Wales want to send Sherratt out on Six Nations high
-
Just looking at images of nature can relieve pain, study finds
-
Guardiola relishing 'big fight' for Champions League qualification
-
Duterte follows ICC hearing over drug war case via videolink
-
Mark Carney to be sworn in as Canada PM
-
Chelsea can be flexible, says Maresca
-
UN migration agency laying off around 20% of HQ staff amid US aid cuts: sources
-
Pique denies Rubiales kickbacks in Spanish Super Cup move to Saudi
-
Tuchel hopes to bring Premier League power to England reign
-
UN chief promises to do "everything" to avoid food cuts to Rohingyas in Bangladesh
-
UniCredit gets ECB nod on Commerzbank stake, but delays merger decision
-
Sri Lanka adjusts train timings to tackle elephant deaths
-
Scotland out to 'disrupt' France's Six Nations title hopes, says Russell
-
BMW expects big hit from tariffs after 2024 profits plunge
-
Bayern's Kim sidelined for 'several weeks' with injury
-
Kremlin says Putin sent 'additional' signals to Trump on ceasefire

Ebola-infected monkeys cured with a pill, raising hopes for humans: study
Monkeys infected with Ebola can be cured with a pill, according to a new study out Friday that could pave the way for more practical, affordable treatments in humans.
First identified in 1976 and thought to have crossed over from bats, Ebola is a deadly viral disease spread through direct contact with bodily fluids, causing severe bleeding and organ failure.
Because outbreaks primarily affect sub-Saharan Africa, pharmaceutical companies have lacked financial incentives to develop treatments, and the sporadic nature of outbreaks has made clinical trials difficult.
A vaccine was only widely approved in 2019, and while two intravenous antibody treatments improve outcomes, they require costly cold storage and are difficult to administer in some of the world's poorest regions.
"We're really trying to come up with something that was more practical, easier to use, that could be used to help prevent, control, and contain outbreaks," Thomas Geisbert, a virologist at The University of Texas Medical Branch at Galveston, who led the new study published in Science Advances, told AFP.
For their experiment, Geisbert and colleagues tested the antiviral Obeldesivir, the oral form of intravenous Remdesivir, originally developed for Covid-19.
Obeldesivir is a "polymerase inhibitor," meaning it blocks an enzyme crucial for viral replication.
The team infected rhesus and cynomolgus macaques with a high dose of the Makona variant of the Ebola virus.
A day after exposure, ten monkeys then received an Obeldesivir pill daily for ten days, while three control monkeys received no treatment and died.
Obeldesivir protected 80 percent of the cynomolgus macaques and 100 percent of the rhesus macaques, which are biologically closer to humans.
The drug not only cleared the virus from the treated monkeys' blood but also triggered an immune response, helping them develop antibodies while avoiding organ damage.
Geisbert explained that while the number of monkeys was relatively small, the study was statistically powerful because they were exposed to an extraordinarily high dose of the virus -- roughly 30,000 times the lethal dose for humans. This reduced the need for additional control monkeys, limiting unnecessary animal deaths.
The researcher, who has worked on Ebola since the 1980s and is credited with discovering the Reston strain, said one of the most exciting aspects of Obeldesivir is its "broad-spectrum" protection, compared to the approved antibody treatments that only work against the Zaire species of Ebola.
"That's a huge advantage," Geisbert said.
Pharmaceutical maker Gilead is currently advancing Obeldesivir to Phase 2 clinical trials for Marburg virus, a close relative of Ebola.
Geisbert also emphasized the importance of funding from the US National Institutes of Health, amid reports that dozens of grants have been canceled under President Donald Trump's administration.
"All these drugs and vaccines that were developed against Ebola and a lot of these exotic viruses and pathogens -- 90 percent of the money comes from the US government," he said, adding, "I think the general public would agree we need treatments for Ebola."
M.Fischer--AMWN